Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
9 hedge funds and large institutions have $585K invested in Cyclo Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
77% less capital invested
Capital invested by funds: $2.58M → $585K (-$2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$280K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$152K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.82K |
| 4 |
Morgan Stanley
New York
|
+$3.44K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.77M |
| 2 |
AC
Armistice Capital
New York
|
-$435K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$386K |
| 4 |
Jane Street
New York
|
-$121K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$68K |
CYTH Hedge Fund Activity: Q1 2021 in Review
9 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q1 2021, worth a combined $585K — down 77% from $2.58M a quarter earlier.
Fund positioning in CYTH was balanced in Q1 2021: 5 funds opened new positions, 5 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $280K. The largest seller was AIGH Capital Management, cutting an estimated $2.77M.
- 9 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $585K of Cyclo Therapeutics, Inc. Common Stock stock for Q1 2021, down 77% quarter-over-quarter.
- 5 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q1 2021 and 5 closed out, a net change of 0 holders.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $280K added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q1 2021 was AIGH Capital Management, an estimated $2.77M sold.
Based on aggregated 13F filings for Q1 2021.